3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
32
Pain, Postoperative
5
Depression
3
Anxiety Disorders
3
Neoplasm Metastasis
2
Fatigue
2
Triple Negative Breast Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Abnormalities
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mastodynia
1
Intranasal Dexmedetomidine Breast Cancer Local Anaesthesia
1
Chronic Pain
1
Chemotherapy-Related Cognitive Impairment
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Neoplasm Malignant Primary
1
Breast Cancer Female
1
Agnosia
1
Interventions
Control Groups
3
Anesthetics, Local
3
Sodium Chloride
2
Magnesium Sulfate
2
Levobupivacaine
2
Ketamine
2
Dental Occlusion
2
Anesthesia, Local
2
Analgesics, Opioid
2
Transdermal Patch
1
Tramadol
1
Surveys and Questionnaires
1
Saline Solution
1
S-Adenosylmethionine
1
Ropivacaine
1
Propofol
1
Pregabalin
1
Nerve Block
1
Musculoskeletal Manipulations
1
Lidocaine
1
Ibuprofen
1
High-Energy Shock Waves
1
Exercise Therapy
1
Exercise
1
Drug Therapy
1
Codeine
1
Capsaicin
1
Bupivacaine
1
Breathing Exercises
1
Botulinum Toxins, Type A
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Agnosia
×
Saline Solution
×
Breast
×
Clear all
NCT00210210
2025-09-19
KETAMINE
Institut Bergonié
Phase 3
Completed
230 enrolled
6 charts